All In Biotech

NDA 203159 · Bayer Hlthcare

Skyla

Levonorgestrel · Intrauterine · Progestin; Progestin-containing Intrauterine System

Last checked: Nov 20, 2026Latest source record: May 4, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jan 9, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

354

70 Phase 3, 26 recruiting

FAERS reports

8,862

4,759 serious, 59 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 4, 2026.

Skyla ® is indicated to prevent pregnancy for up to 3 years. Replace the system after 3 years if continued use is desired. Skyla is a progestin-containing intrauterine system (IUS) indicated for prevention of pregnancy for up to 3 years. ( 1 )

Mechanism: The local mechanism by which continuously released LNG contributes to the contraceptive effectiveness of Skyla has not been conclusively demonstrated. Studies of Skyla and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium .

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SKYLA · LEVONORGESTREL 13.5MG · SYSTEM, INTRAUTERINE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levonorgestrel" as an intervention, any sponsor and status, largest first.

All 354 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device expulsion1,329
  • drug ineffective1,256
  • device dislocation814
  • pregnancy with contraceptive device700
  • genital haemorrhage676
  • abdominal pain lower488
  • procedural pain312
  • expired device used309
  • vaginal haemorrhage299
  • nausea284
  • complication of device insertion258
  • ectopic pregnancy with contraceptive device251

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200439
200539
200637
200727
200822
200945
201064
201193
2012101
2013133
2014351
2015729
2016848
2017939
2018865
2019660
2020644
2021628
2022677
2023625
2024524
2025427
2026345

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Skyla (Levonorgestrel)

2024 spending

$12K

Beneficiaries

12

12 claims

Per beneficiary

$962

$961.90 per unit

View as table
YearSpending
2020$16,273
2021$15,322
2022$14,105
2023$13,442
2024$11,543

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,410 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.